| Kurtis Barry, | |
|
1400 E Boulder St, Colorado Springs, CO 80909-5533 | |
| (719) 365-2525 | |
| Not Available |
| Full Name | Kurtis Barry |
|---|---|
| Gender | Male |
| Speciality | Pharmacist |
| Location | 1400 E Boulder St, Colorado Springs, Colorado |
| Accepts Medicare Assignments | Does not participate in Medicare Program. He may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1023586971 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 183500000X | Pharmacist | 13615 (Colorado) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Kurtis Barry, 3980 Canopy Ct, Colorado Springs, CO 80908-2024 Ph: (303) 345-3437 | Kurtis Barry, 1400 E Boulder St, Colorado Springs, CO 80909-5533 Ph: (719) 365-2525 |
News Archive
Merck & Co., Inc. announced today that the U.S. Centers for Disease Control and Prevention's (CDC's) Advisory Committee on Immunization Practices (ACIP) supports the permissive use of GARDASIL® [Human Papillomavirus Quadrivalent (Types 6, 11, 16 and 18) Vaccine, Recombinant] for boys and young men ages 9 to 26, which means that GARDASIL may be given to males ages 9 to 26 to reduce the likelihood of acquiring genital warts at the discretion of the patient's health care provider.
Multidetector CT (MDCT) cystography (diagnostic procedure used to examine the bladder) can be used to detect vesicourethral leaks (a common problem) after prostatectomy according to a study that was performed at the Seoul National University College of Medicine in the Republic of Korea.
Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that, if Pfizer/Medivation's Dimebon shows efficacy in two ongoing clinical trials in moderate to severe Alzheimer's disease that is equivalent to the impressive clinical trial data it has already shown to date in mild to moderate patients, these positive data would promote the use of Dimebon throughout the course of the disease.
Celgene International SÃ rl, a subsidiary of Celgene Corporation, today announced that REVLIMID (lenalidomide) has been granted approval by the Swiss agency for Therapeutic Products (Swissmedic) for use in patients with transfusion-dependent anemia due to low-or intermediate-1-risk myelodysplastic syndromes (MDS) associated with a deletion 5q cytogenic abnormality with or without additional cytogenic abnormalities.
› Verified 4 days ago
Kristen Lewis, Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 7390 Rangewood Dr, Colorado Springs, CO 80918 Phone: 719-219-1471 | |
Tyrus Loye Papke, Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 9043 Estebury Cir, Colorado Springs, CO 80920 Phone: 719-282-0563 | |
Kevin Reiber, Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 3570 Hartsel Dr, Colorado Springs, CO 80920 Phone: 719-590-7515 Fax: 719-590-7085 | |
Aaron Rubalcaba-lopez, PHARMD Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 8750 N Union Blvd, Colorado Springs, CO 80920 Phone: 719-282-9502 Fax: 719-282-9553 | |
John Charles Theisen, PHARMD Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 3143 W Colorado Ave, Colorado Springs, CO 80904 Phone: 719-632-7112 | |
Maria Alejandra Porras, PHARMD Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 5755 Constitution Ave, Colorado Springs, CO 80915 Phone: 719-591-9929 | |
Billy R Hill, RPH Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 2222 N Nevada Ave, Colorado Springs, CO 80907 Phone: 719-776-5487 |